Literature DB >> 9858673

Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient.

X Li1, D J Hirsh, D Cabral-Lilly, A Zirkel, S M Gruner, A S Janoff, W R Perkins.   

Abstract

We have examined doxorubicin's (DOX) physical state in solution and inside EPC/cholesterol liposomes that were loaded via a transmembrane pH gradient. Using cryogenic electron microscopy (cryo-EM) we noted that DOX loaded to 200-300 mM internal concentrations in citrate containing liposomes formed linear, curved, and circular bundles of fibers with no significant interaction/perturbation of the vesicle membrane. The individual DOX fibers are putatively comprised of stacked DOX molecules. From end-on views of bundles of fibers it appeared that they are aligned longitudinally in a hexagonal array with a separation between fibers of approx. 3-3.5 nm. Two distinct small angle X-ray diffraction patterns (oblique and simple hexagonal) were observed for DOX-citrate fiber aggregates that had been concentrated from solution at either pH 4 or 5. The doxorubicin fibers were also present in citrate liposomes loaded with only one-tenth the amount of doxorubicin used above (approx. 20 mM internal DOX concentration) indicating that the threshold concentration at which these structures form is relatively low. In fact, from cryo-EM and circular dichroism spectra, we estimate that the DOX-citrate fiber bundles can account for the vast majority (>99%) of DOX loaded via a pH gradient into citrate buffered liposomes. DOX loaded into liposomes containing lactobionic acid (LBA), a monoanionic buffer to control the internal pH, remained disaggregated at internal DOX concentrations of approx. 20 mM but formed uncondensed fibers (no bundles) when the internal DOX concentration was approx. 200 mM. This finding suggests that in the citrate containing liposomes the citrate multianion electrostatically bridged adjacent fibers to form the observed bundles. 13C-NMR measurements of [1,5-13C]citrate inside liposomes suggested that citrate 'bound' to the DOX complex and 'free' citrate rapidly exchange indicating that the citrate-DOX interaction is quite dynamic. DOX release into buffer was relatively slow (<4% at 1 h) from liposomes containing DOX fibers (in citrate loaded to a low or high DOX concentration or in LBA liposomes loaded to a high internal DOX concentration). LBA containing liposomes loaded with disaggregated DOX, where the internal DOX concentration was only approx. 20 mM, experienced an osmotic stress induced vesicle rupture with as much as 18% DOX leakage in less than 10 min. The possible implications for this in vivo are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9858673     DOI: 10.1016/s0005-2736(98)00175-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  43 in total

1.  Copper-doxorubicin as a nanoparticle cargo retains efficacy with minimal toxicity.

Authors:  Azadeh Kheirolomoom; Lisa M Mahakian; Chun-Yen Lai; Heather A Lindfors; Jai Woong Seo; Eric E Paoli; Katherine D Watson; Eric M Haynam; Elizabeth S Ingham; Li Xing; R Holland Cheng; Alexander D Borowsky; Robert D Cardiff; Katherine W Ferrara
Journal:  Mol Pharm       Date:  2010-12-06       Impact factor: 4.939

2.  Complete regression of local cancer using temperature-sensitive liposomes combined with ultrasound-mediated hyperthermia.

Authors:  Azadeh Kheirolomoom; Chun-Yen Lai; Sarah M Tam; Lisa M Mahakian; Elizabeth S Ingham; Katherine D Watson; Katherine W Ferrara
Journal:  J Control Release       Date:  2013-08-28       Impact factor: 9.776

3.  Capillary electrophoresis monitors enhancement in subcellular reactive oxygen species production upon treatment with doxorubicin.

Authors:  Angela R Eder; Edgar A Arriaga
Journal:  Chem Res Toxicol       Date:  2006-09       Impact factor: 3.739

4.  Light-induced self-assembly of nanofibers inside liposomes.

Authors:  Hyung-Kun Lee; Stephen Soukasene; Hongzhou Jiang; Shuming Zhang; Wenchun Feng; Samuel I Stupp
Journal:  Soft Matter       Date:  2008-05-01       Impact factor: 3.679

5.  Design of liposomal colloidal systems for ocular delivery of ciprofloxacin.

Authors:  Ehab I Taha; Magda H El-Anazi; Ibrahim M El-Bagory; Mohsen A Bayomi
Journal:  Saudi Pharm J       Date:  2013-08-08       Impact factor: 4.330

6.  Formulation and characterisation of magnetic resonance imageable thermally sensitive liposomes for use with magnetic resonance-guided high intensity focused ultrasound.

Authors:  Ayele H Negussie; Pavel S Yarmolenko; Ari Partanen; Ashish Ranjan; Genevieve Jacobs; David Woods; Henry Bryant; David Thomasson; Mark W Dewhirst; Bradford J Wood; Matthew R Dreher
Journal:  Int J Hyperthermia       Date:  2011       Impact factor: 3.914

7.  Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance.

Authors:  Jiayi Pan; Livia P Mendes; Momei Yao; Nina Filipczak; Sumanta Garai; Ganesh A Thakur; Can Sarisozen; Vladimir P Torchilin
Journal:  Eur J Pharm Biopharm       Date:  2019-01-08       Impact factor: 5.571

Review 8.  Novel approaches to treatment of hepatocellular carcinoma and hepatic metastases using thermal ablation and thermosensitive liposomes.

Authors:  Mark W Dewhirst; Chelsea D Landon; Christina L Hofmann; Paul R Stauffer
Journal:  Surg Oncol Clin N Am       Date:  2013-03-13       Impact factor: 3.495

9.  Nanoscale Drug Delivery and Hyperthermia: The Materials Design and Preclinical and Clinical Testing of Low Temperature-Sensitive Liposomes Used in Combination with Mild Hyperthermia in the Treatment of Local Cancer.

Authors:  Chelsea D Landon; Ji-Young Park; David Needham; Mark W Dewhirst
Journal:  Open Nanomed J       Date:  2011-01-01

10.  Short-chain glycoceramides promote intracellular mitoxantrone delivery from novel nanoliposomes into breast cancer cells.

Authors:  Lília R Cordeiro Pedrosa; Timo L M Ten Hagen; Regine Süss; Albert van Hell; Alexander M M Eggermont; Marcel Verheij; Gerben A Koning
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.